Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (1,244) Arrow Down
Filter Results: (1,244) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,244)
    • People  (5)
    • News  (171)
    • Research  (928)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (756)

Show Results For

  • All HBS Web  (1,244)
    • People  (5)
    • News  (171)
    • Research  (928)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (756)
← Page 15 of 1,244 Results →
  • August 2013
  • Teaching Plan

Remicade-Simponi

By: Guhan Subramanian and Charlotte Krontiris
This exercise models a negotiation between two pharmaceutical companies—Johnson & Johnson and Merck—concerning the international distribution rights for Remicade, a blockbuster anti-arthritis drug. At odds over the original distribution contract, the two companies... View Details
Keywords: Johnson & Johnson; Merck; Negotiation; Negotiation Participants; Negotiation Deal; Pharmaceutical Industry
Citation
Purchase
Related
Subramanian, Guhan, and Charlotte Krontiris. "Remicade-Simponi." Harvard Business School Teaching Plan 914-006, August 2013.
  • November 2006
  • Case

Selling Biovail Short

By: Malcolm P. Baker, Chris Lombardi and Aldo Sesia
Hedge fund SAC Capital and analysts from Gradient Analytics and Banc of America face charges of stock price manipulation from Biovail, a Canadian pharmaceutical company. Gradient and BofA produced negative reports on Biovail's earnings quality. At the same time, SAC... View Details
Keywords: Stock Shares; Investment Banking; Asset Pricing; Financial Strategy; Crime and Corruption; Pharmaceutical Industry; Pharmaceutical Industry; Canada
Citation
Educators
Purchase
Related
Baker, Malcolm P., Chris Lombardi, and Aldo Sesia. "Selling Biovail Short." Harvard Business School Case 207-071, November 2006.
  • August 2013 (Revised October 2013)
  • Case

MedImmune Ventures

By: Richard G. Hamermesh and David Lane
Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details
Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; Australia; Europe; London
Citation
Educators
Purchase
Related
Hamermesh, Richard G., and David Lane. "MedImmune Ventures." Harvard Business School Case 814-023, August 2013. (Revised October 2013.)
  • August 2003 (Revised August 2006)
  • Case

New Sector Alliance (A): An Entry into Health Care?

By: Regina E. Herzlinger, Stacy Smollin Schwartz and Jeffrey Cronin
Describes the structure of the U.S. health care system and presents a study of a nonprofit consulting firm that hopes to enter the health care system. Includes descriptions of hospitals, doctors, insurers, medical technology providers, medical devices, pharmaceuticals,... View Details
Keywords: Health; Health Care and Treatment; Health Disorders; Nonprofit Organizations; Health Industry; United States
Citation
Find at Harvard
Related
Herzlinger, Regina E., Stacy Smollin Schwartz, and Jeffrey Cronin. "New Sector Alliance (A): An Entry into Health Care?" Harvard Business School Case 304-004, August 2003. (Revised August 2006.)
  • February 1997
  • Case

Archer Daniels Midland: Direction and Strategy

By: Ray A. Goldberg and Thomas N. Urban Jr
Sets out the strategy and competitive competencies of one of the leading grain trade and processing companies in the world. An overview of the company's innovations in corn and oilseed by-products is provided. The strategy of the firm is to add by-products to corn,... View Details
Keywords: Innovation and Invention; Strategic Planning; Business Strategy; Value Creation; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Goldberg, Ray A., and Thomas N. Urban Jr. "Archer Daniels Midland: Direction and Strategy." Harvard Business School Case 597-039, February 1997.
  • January 2001 (Revised May 2003)
  • Case

Novartis Pharma: The Business Unit Model

By: Srikant M. Datar, Carin-Isabel Knoop and Cate Reavis
In June 2000, Novartis reorganized its pharmaceutical business to form global business units in oncology, transplantation, ophthalmology, and mature products. The remaining primary care products continued to be managed within global functions (e.g., R&D and marketing).... View Details
Keywords: Restructuring; Recruitment; Product Marketing; Organizational Structure; Problems and Challenges; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Datar, Srikant M., Carin-Isabel Knoop, and Cate Reavis. "Novartis Pharma: The Business Unit Model." Harvard Business School Case 101-030, January 2001. (Revised May 2003.)
  • 26 Feb 2012
  • News

Can brand Mallya make Kingfisher Airlines fly?

  • Research Summary

AIDS in Africa: Life, Death and Property Rights

By: Debora L. Spar
In the final years of the twentieth century, the world was hit by a plague of epidemic proportions--the plague of AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought... View Details
  • 26 Mar 2018
  • News

She Was Given Three Years To Live. So She Transformed Cancer Research

  • February 1996
  • Case

Chadwick, Inc.: The Balanced Scorecard (Abridged)

By: Robert S. Kaplan
The pharmaceutical division of a diversified company has been asked to develop a Balanced Scorecard. Research and development projects take about ten years to bring a new product to the marketplace and the division depends on good relations and active feedback from its... View Details
Keywords: Balanced Scorecard; Research and Development; Product Launch; Commercialization; Consumer Behavior; Customer Focus and Relationships; Performance Evaluation; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Kaplan, Robert S. "Chadwick, Inc.: The Balanced Scorecard (Abridged)." Harvard Business School Case 196-124, February 1996.
  • January 1994 (Revised July 1998)
  • Case

Repligen Corporation: January 1992

By: Josh Lerner and David Kane
Sandford Smith, CEO of Repligen, faces the breakdown of negotiations about a proposed joint venture with a large pharmaceutical firm. He must decide whether to proceed using his firm's internal resources or whether to seek to revise the proposed collaboration. If the... View Details
Keywords: Joint Ventures; Decisions; Contracts; Agreements and Arrangements; Value
Citation
Educators
Purchase
Related
Lerner, Josh, and David Kane. "Repligen Corporation: January 1992." Harvard Business School Case 294-082, January 1994. (Revised July 1998.)
  • 15 Feb 2018
  • News

Does CVS–Aetna Spell the End of Business as Usual?

  • 06 Jan 2021
  • News

Covid-19 Case Studies Make Their Way Into M.B.A. Curricula

  • April 2009 (Revised November 2012)
  • Case

Sermo, Inc.

By: Thomas R. Eisenmann and Lars Peter Christian Nielsen
Sermo operates the leading online professional network for physicians in the United States. Doctors use Sermo free of charge to post surveys regarding diagnostic and treatment concerns and to discuss these concerns, as well as challenges with managing their practices.... View Details
Keywords: Entrepreneurship; Health Care and Treatment; Knowledge Sharing; Two-Sided Platforms; Conflict and Resolution; Social and Collaborative Networks; United States
Citation
Educators
Purchase
Related
Eisenmann, Thomas R., and Lars Peter Christian Nielsen. "Sermo, Inc." Harvard Business School Case 809-142, April 2009. (Revised November 2012.)
  • March 1994 (Revised April 1994)
  • Case

Eli Lilly and Co.: The Flexible Facility Decision--1993

By: Gary P. Pisano
In 1993, Eli Lilly is preparing to build manufacturing capacity for three new pharmaceutical products that it expects to launch in 1996. Management wrestles with a decision of whether to add specialized manufacturing capacity or flexible capacity. This question touches... View Details
Keywords: Debates; Cost vs Benefits; Decisions; Investment; Goals and Objectives; Product Launch; Production; Corporate Strategy; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Pisano, Gary P. "Eli Lilly and Co.: The Flexible Facility Decision--1993." Harvard Business School Case 694-074, March 1994. (Revised April 1994.)
  • Awards

Dan and Mary Lou Schendel Best Paper Prize

By: Rebecca M. Henderson
Won the 2010 Dan and Mary Lou Schendel Best Paper Award from the Strategic Management Society for her paper with Ian Cockburn, "Measuring Competence? Exploring Firm Effects in Pharmaceutical Research" (Strategic Management Journal, 1994). The award is for a... View Details

    Case: The Allergan Board Under Fire (A)

    In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge... View Details
    • March 2008 (Revised March 2022)
    • Case

    Cadbury Schweppes: Capturing Confectionery (A)

    By: David Collis, Toby Stuart and Troy Smith
    In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a... View Details
    Keywords: Business History; Strategy; Decision Choices and Conditions; Mergers and Acquisitions; Food and Beverage Industry
    Citation
    Educators
    Purchase
    Related
    Collis, David, Toby Stuart, and Troy Smith. "Cadbury Schweppes: Capturing Confectionery (A)." Harvard Business School Case 708-453, March 2008. (Revised March 2022.)
    • Article

    One Obstacle to Curing Cancer: Patient Data Isn't Shared

    By: Richard G. Hamermesh and Kathy Giusti
    Precision Medicine requires large datasets to identify the mutations that lead to various cancers. Currently, genomic information is hoarded in fragmented silos within numerous academic medical centers, pharmaceutical companies, and some disease-based foundations. For... View Details
    Keywords: Healthcare; Technological And Scientific Innovation; Cancer Care In The U.S.; Cancer Treatment; Precision Medicine; Personalized Medicine; Data Sharing; Technological Innovation; Analytics and Data Science; Health Disorders; Medical Specialties; Research and Development; Customization and Personalization; Health Industry; United States
    Citation
    Register to Read
    Related
    Hamermesh, Richard G., and Kathy Giusti. "One Obstacle to Curing Cancer: Patient Data Isn't Shared." Harvard Business Review (website) (November 28, 2016).
    • March 2014 (Revised December 2014)
    • Case

    Vision 2020: Takeda and the Vaccine Business

    By: John A. Quelch and Margaret L. Rodriguez
    In 2014, Yasuchika Hasegawa was orchestrating the transformation of Takeda from a Japanese pharmaceutical company with a global footprint into a global company with a Japanese heritage. A 33-year veteran of Takeda, Hasegawa-san was appointed president of Takeda in 2003... View Details
    Keywords: Health Care; Global; NGO; Public Health; Japan; GSK; Vaccine; Supply Chain; Market Entry; Health; Health Care and Treatment; Trade; Market Entry and Exit; Global Strategy; Pharmaceutical Industry; Pharmaceutical Industry
    Citation
    Educators
    Purchase
    Related
    Quelch, John A., and Margaret L. Rodriguez. "Vision 2020: Takeda and the Vaccine Business." Harvard Business School Case 514-084, March 2014. (Revised December 2014.)
    • ←
    • 15
    • 16
    • …
    • 62
    • 63
    • →
    ǁ
    Campus Map
    Harvard Business School
    Soldiers Field
    Boston, MA 02163
    →Map & Directions
    →More Contact Information
    • Make a Gift
    • Site Map
    • Jobs
    • Harvard University
    • Trademarks
    • Policies
    • Accessibility
    • Digital Accessibility
    Copyright © President & Fellows of Harvard College.